Non‐invasive assessment of hepatic steatosis by ultrasound‐derived fat fraction in individuals at high‐risk for metabolic dysfunction‐associated steatotic liver disease
- 10 March 2024
- journal article
- research article
- Published by Wiley in Diabetes/Metabolism Research and Reviews
- Vol. 40 (3) , e3787
Abstract
Aims: Given the increasing number of individuals developing metabolic dysfunction‐associated steatotic liver disease (MASLD) and the low rate of those with progressive liver disease, there is a pressing need to conceive affordable biomarkers to assess MASLD in general population settings. Herein, we aimed to investigate the performance of the ultrasound‐derived fat fraction (UDFF) for hepatic steatosis in high‐risk individuals.Methods: A total of 302 Europeans with obesity, type 2 diabetes, or a clinical history of hepatic steatosis were included in the analyses. Clinical, laboratory, and imaging data were collected using standardized procedures during a single screening visit in Rome, Italy. Hepatic steatosis was defined by controlled attenuation parameter (CAP) or ultrasound‐based Hamaguchi's score. UDFF performance for hepatic steatosis was estimated by the area under the receiver operating characteristic curve (AUC).Results: Overall, median (IQR) UDFF was 12% (7–20). UDFF was positively correlated with CAP (ρ = 0.73, p < 0.0001) and Hamaguchi's score (ρ = 0.79, p < 0.0001). Independent predictors of UDFF were circulating triglycerides, alanine aminotransferase (ALT), and ultrasound‐measured visceral adipose tissue (VAT). UDFF AUC was 0.89 (0.85–0.93) and 0.92 (0.88–0.95) for CAP‐ and ultrasound‐diagnosed hepatic steatosis, respectively. UDFF AUC for hepatic steatosis was higher than those of fatty liver index (FLI), hepatic steatosis index (HSI), CAP‐score (CAPS), and ALT (p < 0.0001). Lower age, ALT, and VAT were associated with discordance between UDFF and ultrasound.Conclusions: UDFF may be a simple and accurate imaging biomarker to assess hepatic steatosis and monitor changes in hepatic fat content over time or in response to therapeutic interventions beyond clinical trials.Keywords
Funding Information
- Ministero della Salute (RF‐2021‐12374481)
- Ministero dell'Università e della Ricerca (PRIN 2022BZFFFY)
This publication has 29 references indexed in Scilit:
- Predictors of controlled attenuation parameter in metabolic dysfunctionUnited European Gastroenterology Journal, 2023
- Mechanisms and disease consequences of nonalcoholic fatty liver diseaseCell, 2021
- Ultrasound measures of abdominal fat layers correlate with metabolic syndrome features in patients with obesityObesity Science & Practice, 2020
- Novel Method for Ultrasound‐Derived Fat Fraction Using an Integrated PhantomJournal of Ultrasound in Medicine, 2020
- Vibration-Controlled Transient Elastography to Assess Fibrosis and Steatosis in Patients With Nonalcoholic Fatty Liver DiseaseClinical Gastroenterology and Hepatology, 2019
- Noninvasive, Quantitative Assessment of Liver Fat by MRI‐PDFF as an Endpoint in NASH TrialsHepatology, 2018
- Utility of magnetic resonance imaging versus histology for quantifying changes in liver fat in nonalcoholic fatty liver disease trialsHepatology, 2013
- Liver biopsy†Hepatology, 2009
- Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III)JAMA, 2001
- Homeostasis model assessment: insulin resistance and ?-cell function from fasting plasma glucose and insulin concentrations in manDiabetologia, 1985